Rafarma Pharmaceuticals Stock Total Asset
| RAFA Stock | USD 0.09 0 4.40% |
Rafarma Pharmaceuticals fundamentals help investors to digest information that contributes to Rafarma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rafarma Pink Sheet. The fundamental analysis module provides a way to measure Rafarma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rafarma Pharmaceuticals pink sheet.
Rafarma |
Rafarma Pharmaceuticals Company Total Asset Analysis
Rafarma Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Rafarma Pharmaceuticals Total Asset | 460.33 M |
Most of Rafarma Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rafarma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Rafarma Pharmaceuticals has a Total Asset of 460.33 M. This is 93.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total asset for all United States stocks is 98.44% higher than that of the company.
Rafarma Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rafarma Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rafarma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rafarma Pharmaceuticals by comparing valuation metrics of similar companies.Rafarma Pharmaceuticals is currently under evaluation in total asset category among its peers.
Rafarma Fundamentals
| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.88) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 7.89 M | |||
| Price To Earning | (1.29) X | |||
| Price To Sales | 857.77 X | |||
| Net Income | (14.85 K) | |||
| Book Value Per Share | 40.49 X | |||
| Cash Flow From Operations | (1 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -0.39 | |||
| Market Capitalization | 110.29 M | |||
| Total Asset | 460.33 M | |||
| Retained Earnings | (2.38 M) | |||
| Current Liabilities | 292 K | |||
| Net Asset | 460.33 M |
About Rafarma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rafarma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rafarma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rafarma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.